BeyondSpring presented interim Phase 2 data on 303 Study

BeyondSpring (BYSI) presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer, NSCLC, after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy, with financial support from Merck (MRK) Investigator Studies Program and provision of study drug, at the European Society for Medical Oncology, ESMO, Congress 2024, on September 14, 2024 in Barcelona, Spain. Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations who progress on 1L immune checkpoint inhibitors with and without standard chemotherapy, with an overall response rate, ORR, of 12.8% and median PFS of 3.7 months in TROPION Lung-01 phase 3 studies. In metastatic NSCLC resistant to previous PD-1/L1 therapy1, PD-L1 and CTLA-4 inhibition alone or in combination with hypofractionated radiotherapy produced limited clinical benefits with ~11.5% ORR.